Dr. Davr is a translational oncologist whose research interests lies in translational cancer immunotherapy and early-phase clinical trials. He has been instrumental in the development of first-in-human studies evaluating novel agents targeting TIGIT, GITR, TIM-3, CTLA-3 and other immune checkpoints. Based on emerging data implicating intestinal dysbiosis in mediating non-response to PD-1 blockade, he developed a protocol evaluating fecal microbiota transplant in combination with PD-1 blockade to treat PD-1 non-responders. This first-in-human study was selected for funding by Merck to support the clinical costs. Results demonstrating that microbiome modulation reversed primary resistance to anti-PD-1 and augmented anti-tumor immunity were recently published in Science.